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Abstract
Background: There has been increasing debate surrounding mask and respirator interventions to control
respiratory infection transmission in both healthcare and community settings. As decision makers are considering
the recommendations they should evaluate how to provide the most efficient protection strategies with minimum
costs. The aim of this review is to identify and evaluate the existing economic evaluation literature in this area and
to offer advice on how future evaluations on this topic should be conducted.
Methods: We searched the Scopus database for all literature on economic evaluation of mask or respirator use to
control respiratory infection transmission. Reference lists from the identified studies were also manually searched.
Seven studies met our inclusion criteria from the initial 806 studies identified by the search strategy and our
manual search.
Results: Five studies considered interventions for seasonal and/or pandemic influenza, with one also considering
SARS (Severe Acute Respiratory Syndrome). The other two studies focussed on tuberculosis transmission control
interventions. The settings and methodologies of the studies varied greatly. No low-middle income settings were
identified. Only one of the reviewed studies cited clinical evidence to inform their mask/respirator intervention
effectiveness parameters. Mask and respirator interventions were generally reported by the study authors to be cost
saving or cost-effective when compared to no intervention or other control measures, however the evaluations had
important limitations.
Conclusions: Given the large cost differential between masks and respirators, there is a need for more
comprehensive economic evaluations to compare the relative costs and benefits of these interventions in situations
and settings where alternative options are potentially applicable. There are at present insufficient well conducted
cost-effectiveness studies to inform decision-makers on the value for money of alternative mask/respirator options.
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Background
Both the World Health Organisation (WHO) and the
Centre for Disease Control (CDC) guidelines recom-
mend the use of a mask in low-risk settings and a respir-
ator in high-risk settings (e.g. during aerosol generating
procedures) to protect healthcare workers (HCWs) from
seasonal influenza [1, 2]. The use of a respirator at all
times is also advised for HCWs caring for patients with
suspected infectious tuberculosis [3, 4]. These measures
are important to protect HCWs as well as to reduce the
spread of respiratory infections within hospitals. This
can help to reduce both the costs associated with HCW
absenteeism and the costs of nosocomial infections.
Mask/respirator availability may also prove crucial in
the context of newly emerging respiratory infections,
particularly as some diseases such as SARS (Severe
Acute Respiratory Syndrome) and MERS-CoV (Middle
East Respiratory Syndrome Coronavirus) may initially
have no vaccine or treatment available, leaving non-
pharmaceutical measures as the only available protection
for HCWs. For other diseases such as pandemic
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influenza, reliance on vaccines for protection is not al-
ways possible due to time delays in vaccine
development, manufacturing and distribution [5]. Fur-
thermore, the stockpiling of relatively expensive antivi-
rals for influenza pandemics may not be cost-effective in
low and middle income settings [6].
In the absence of standardised mask/respirator no-
menclature [7], we will use the term ‘mask’ to indicate
standard surgical masks, also referred to as “medical
masks” in some countries. These are not specially engi-
neered to protect the wearer from aerosol transmission
of droplet nuclei and viral particles [8, 9]. ‘Respirator’
will be used to denote all personal protective facemasks
engineered for filtration and fit to prevent the transmis-
sion of respiratory viruses and aerosol droplets. Several
air purifying respirators that filter the inhaled air through
filtering materials are available for use by HCWs [10],
these include: N95, HEPA (high-efficiency particulate air),
PARP (powered air purifying respirator), DM (dust-mist)
and DMF (dust-mist-fume).
There are substantial differences in cost between dif-
ferent mask/respirator options. These cost differences
may be an important determinant in the development of
country specific mask/respirator guidelines for HCWs.
For example, the more costly PARP is only recom-
mended in the guidelines for high income countries [7].
Many countries’ guidelines recommend fit testing and
training sessions for respirator use, but contain limited
descriptions of what this should entail [7]. Fit testing can
be qualitative or quantitative, with the latter being more
expensive and adding a substantial cost to respirator use
but not to mask use, which does not require fit testing
[10].
Two studies evaluating mask/respirator use [11, 12]
were included in a previous economic review of influenza
pandemic measures [13]. There are a small but growing
number of economic evaluations for masks/respirators.
The aim of this review is to identify and evaluate this
existing literature and offer advice on how future evalua-
tions on this topic should be conducted.
Methods
The Scopus database was searched for all English-
language literature on the economic evaluation of
mask or respirator use for the control of respiratory
infection transmission. Scopus includes 100 % cover-
age of both MEDLINE and EMBASE [14]. The major-
ity of the relevant literature identified in the initial
Scopus search included influenza or tuberculosis as
either the single focus or one of the diseases to
control. For this reason, these terms (influenza OR
tuberculosis) were used in addition to the generic
terms related to infection and transmission, i.e. they
did not prevent the identification of articles focused
on other infectious respiratory diseases. The final
search strategy contained publications until the 1st of
August 2014, and used the search terms (as keyword,
title or abstract): ‘facemask*’ (or ‘mask*’ or ‘respirator’
or ‘N95’ or ‘non$pharm*’ or ‘{personal protect*}’)
AND ‘economic*’ (or ‘cost*’) AND ‘infect*’ (or ‘transmi*’
or ‘influenza’ or ‘tuberculosis’).
The 806 results from this initial Scopus search were
screened (Fig. 1). The abstracts of these articles were
reviewed on the basis of whether they were economic
evaluations (e.g. cost-effectiveness, cost-utility or cost-
benefit studies), and whether the intervention being
evaluated involved masks and/or respirators as a strategy
to prevent the transmission of respiratory infections.
From this process, 112 full text articles were considered
potentially relevant and their full texts were further
reviewed for eligibility. Of these, only six were confirmed
to be economic evaluations of mask or respirator in-
fection control interventions. One additional study by
Dan et al. [12] was identified from the reference list
of a systematic review [13]. These were the main
studies used in our qualitative synthesis. Four other
costing studies [15–18] have been published but these
examined the cost of the intervention only and were
not classified as full economic evaluations (i.e. they
did not examine the health impacts or the cost sav-
ings from prevented illness). Data from the included
studies was independently extracted intro a spread
sheet by SM and this was reviewed by ATN.
Fig. 1 Flow diagram for study inclusion
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Disagreements were resolved by discussion between
these authors.
Results
Description of economic evaluations identified
Seven economic evaluations of mask/respirator use in
the control of respiratory infections were identified
(Table 1) [11, 12, 19–23]. These studies varied widely in
their settings and methodologies. The studies by Adal et
al. [19] and Nettleman et al. [23] were published in 1994
and were on tuberculosis in healthcare settings. Five
others (published post 2008) were focused on seasonal
or pandemic influenza [11, 12, 20–22]. One of these by
Dan et al. [12] also considered a SARS scenario. Other
than this study, to date, no other mask/respirator eco-
nomic evaluations have been identified that focus on
SARS, MERS-CoV or other respiratory viruses (other
than influenza). There were also no economic evaluation
studies identified on mask or respirator use to prevent
transmission of Ebola.
The interventions evaluated by the studies included
N95 respirators [12, 20, 22], HEPA, DM and DMF
respirators [19, 23], and surgical masks [19–21, 23].
Amongst the studies that focused on influenza, two
of the five, by Dan et al. [12] and Chen and Liao
[21], integrated mask/respirator use in a scenario in
conjunction with other non-pharmaceutical control
measures e.g. natural ventilation [21] or isolation
measures [12], as opposed to evaluating the use of
masks/respirators exclusively. This makes it difficult
to assess to what degree the mask/respirator aspect of
the intervention is driving the cost-effectiveness, or if
the results are more attributable to the other control
measures included.
The settings of the evaluated studies varied more
broadly for the influenza studies than for those on tuber-
culosis. Three of the five influenza studies were in a
community setting [11, 20, 22]. Of the others, one con-
sidered control measures for both the community and
hospital setting [12] and the last was set in a primary
school [21]. All of the seven identified studies were set
in the USA or other developed countries, limiting the
generalisability of the findings, e.g. for decision making
in low resource settings. The lack of studies in low re-
source settings has been cited as one of the major im-
pediments to the use of cost-effectiveness analysis for
pandemic influenza preparedness planning in this con-
text [24].
Intervention outcome measures
Four of the five influenza studies included the number
of infection cases as one of the outcome measures of
intervention effectiveness (Table 1) [11, 12, 21, 22]. The
remaining influenza study quantified and reported the
consequences of infection on other outcomes e.g.
prevented deaths, hospitalisations, outpatient visits and
absenteeism [20].
Both tuberculosis studies measured conversion rates of
newly positive protein derivative tests in HCWs at study
hospitals [19, 23]. A positive test indicates a 5–10 %
chance that the individual will develop active tubercu-
losis in their lifetime [25]. One of the two studies also
estimated the number of patients isolated for known tu-
berculosis per month, confirmed pulmonary tuberculosis
cases in patients in the past year and active cases of pul-
monary tuberculosis in HCWs in the last 5 years [23].
This additional information provided a more complete
measure of the impact of the intervention.
Cost-effectiveness outcomes
Only three [12, 19, 23] of the seven studies reported re-
sults as cost per unit of effect. The evaluation by Dan et
al. [12] of influenza and SARS reported an incremental
cost per death averted [12]. The other two were the tu-
berculosis studies, with one reporting the cost to prevent
a single occupational case of tuberculosis in the next
41 years [19] and the other reporting the cost per tuber-
culosis case prevented and the cost per life saved [23].
Two of the pandemic influenza studies evaluating com-
binations of interventions in the community con-
cluded that mask/respirator interventions were cost
saving in a pandemic setting [11, 22]. The first esti-
mated substantial net savings if 10 % of the population
had worn N95 respirators during influenza
A(H1N1)pdm09, assuming an effectiveness of 20 %
[11]. The second estimated that surgical mask use at
60 % compliance would yield savings of $US100-250
million, far exceeding the estimated intervention cost
of $US20 million [20]. The influenza modelling stud-
ies by Jones and Adida [22] focused on demonstrating
the feasibility of the methods rather than reporting
key economic results. The influenza study by Chen
and Liao [21] calculated a cost per individual to im-
plement control measures, but limited the inclusion
of costs to intervention and outpatient treatments
costs.
Mask and respirator effectiveness or “strategy impact”
Approaches to incorporate intervention effectiveness
amongst the seven studies varied (Table 1). Both of
the tuberculosis evaluations by Adal et al. [19] and
Nettleman et al. [23] reported that no efficacy studies
were available and thus no specific measures of mask
or respirator effectiveness were included in their eval-
uations. Nettleman et al. [23] assumed that in a best
case scenario, HEPA respirators would prevent 25 %
of HCW exposure to tuberculosis, but no data was
cited to support this estimate. Adal et al. [19]
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Table 1 Descriptive and methodological details of identified mask and respirator economic evaluations
First author, year,
setting
Jones and Adida, 2013 [22],
European contact rates
Chen and Liao, 2013
[21], Taiwan
Tracht et al, 2012
[11], USA
Dan et al, 2009 [12],
Singapore
Cahill et al, 2008
[20], USA




Infection(s) Influenza epidemic Seasonal influenza Influenza
A(H1N1)pdm09
Influenza A(H1N1)pdm09,











Mask intervention 1 mask/person/day
for duration of epidemic
(90 days). Assumed
respirator use begins
when 0.05 % population
infected
Surgical mask use and
natural ventilation
N95 respirator use
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duration of pandemic,
starting when 0.001 %
symptomatic
Green 0: no intervention,
Green 1: PPE for HCWs in
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cases, Yellow: full PPE for
HCWs in high risk contact,
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implicitly assumed that all HCW cases of tuberculosis
that may have been acquired from patients in isola-
tion with active tuberculosis would be prevented by
the intervention.
Of the five influenza studies, Tracht et al. [11] was the
only study that attempted to utilise clinical efficacy data.
They obtained this from a randomised trial in a univer-
sity residence setting [26] that found a significant de-
crease (35–51 %) in influenza-like illness if hand hygiene
and medical masks were used together compared to a
control, but no difference for medical mask use alone.
Tracht et al. [11] uses this result to estimate N95 respir-
ator use provides a 50 % decrease in susceptibility to in-
fluenza A(H1N1)pdm09. This may not be robust as the
clinical trial measured different outcomes (i.e. influenza-
like illness, not influenza A(H1N1)pdm09 cases) and it
assumes there is no difference between the efficacy of
medical masks and N95 respirators based on the find-
ings of Loeb et al. [27], although other trials have found
evidence that there is a difference [28]. The study by
Jones and Adida [22] derived efficacy estimates from the
assigned protective factor (APF) measure for N95 respi-
rators released by the National Institute for Occupa-
tional Safety and Health [29]. The APF is estimated from
laboratory testing completed by this organisation, in-
cluding laboratory testing of the quantitative measure of
fit when the respirators are fit tested to ensure a protect-
ive seal around the wearer’s face. Cahill et al. [20] also
used efficacy estimates from laboratory investigation
data [30]. These estimates may have limited applicability
to measuring real-world effectiveness [31]. Dan et al.
[12] estimated baseline intervention effectiveness rates
of 50, 80 and 90 % as protective equipment (including
masks) and isolation precautions were increased. They
did not cite data to support these estimates, however a
5 % failure rate where transmission still occurs despite
the use of protective equipment and isolation measures,
was obtained from a hospital simulation study [32].
Chen and Liao [21] applied a relative efficacy estimate of
masks in combination with other control measures
which was developed in a previous modelling study
that did not cite supporting data for efficacy input as-
sumptions [33]. Other than Tracht et al. [11], none of
the analyses used intervention effectiveness estimates
from clinical trials such as the mask/respirator rando-
mised trials that have been published to date on in-
terventions in community and healthcare settings
[26–28, 34–38].
Costs
Only two of the seven evaluations, by Dan et al. [12] and
Jones and Adida et al. [22], explicitly stated the eco-
nomic perspective from which they had conducted their
evaluation, these being a policy developer view [22] and
the healthcare institution perspective [12]. On the basis
of costs included and excluded, four of the seven
studies are most aligned with healthcare payer per-
spectives [12, 19, 21, 23] and the remaining three
with a societal perspective [11, 20, 22] (e.g. they
included some form of productivity costs). Both
tuberculosis evaluations by Adal et al. [19] and
Nettleman et al. [23], considered costs from a health-
care provider perspective, reflecting the objective of
preventing the burden of nosocomial cases in HCWs
and patients. The influenza studies [11, 20, 22] more
frequently applied a societal perspective, consistent
with the substantial economic impact of productivity
losses due to influenza absenteeism [39].
The reporting of costs included in the evaluations was
often not transparent. One evaluation by Dan et al. [12]
identified the omission of the indirect costs of lost rev-
enue from the cancellation of elective surgeries, de-
creased outpatient attendance, lost clinical teaching time
and administration costs of senior staff meetings. These
costs were not discussed in other influenza modelling
studies where they may have been relevant [11, 20, 22].
The tuberculosis studies by Adal et al. [19] and
Nettleman et al. [23] relied on hospital databases for
the number of masks/respirators used, and multi-
plied this by unit costs to calculate total costs. Ad-
ministration costs were most thoroughly reported in
the tuberculosis study by Adal et al. [19], which in-
cluded staff program planning time and staff medical
evaluation time.
All of the studies that estimated a cost per case, in-
cluded the cost of infected individuals [11, 12, 20–22].
For example, one influenza modelling study by Jones
and Adida [22] assumed a fixed average cost for each in-
fection. This may not always be an ideal method to cost
resources used as the cost of an average case may vary
amongst patients [40]. Tracht et al. [11] allocated a sep-
arate average hospital cost per day due to influenza
A(H1N1)pdm09 infections for three age groups.
Approaches to model adherence to interventions
Three of the studies evaluating the intervention in the
community included the impact of compliance [11, 20,
22]. These included simple approaches, as used by Cahill
et al. [20] of assessing 60 and 100 % adherence scenar-
ios, as well as by Jones and Adida [22] where an estimate
of 50 % compliance was assumed. Tracht et al. [11]
conducted a more thorough sensitivity analysis by
dividing the population into three age groups and
testing three scenarios with different proportions of
compliance in each group. No study attempted to use
compliance rates from real-world investigations such
as clinical trials [28, 36].
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Discussion
There were a relatively small number of economic evalua-
tions of mask/respirator use that met the inclusion criteria
and no existing studies were found that address the cost-
effectiveness of these interventions in low-middle income
countries. The seven evaluations identified have limited
utility to advise decision makers on the value for money
that masks and respirators offer compared with other
health spending choices. This is due to the reporting of re-
sults in the form of intermediate outcomes (e.g. case pre-
vented) and the analysis of combinations of masks/
respirators with other protection measures in evaluations
[12, 21, 22]. There was also limited inclusion of clinical
data to inform the effectiveness estimates and the impact
of intervention compliance in the identified studies. Com-
pliance has major implications for a mask/respirator
intervention targeting HCWs [9]. For example, obtaining
high adherence in HCWs has not been feasible in
some high-income countries such as Australia [41]. Vari-
ation in HCW mask/respirator compliance has been
observed between countries, such as the lower rates
seen in UK hospitals compared to Hong Kong
and Singapore during influenza A(H1N1)pdm09 [42].
Mask/respirator adherence is primarily driven by perceived
susceptibility to the infectious disease threats present
[43–48].
What clinical evidence is there on comparative mask and
respirator effectiveness?
Only one of the reviewed studies [11] cited clinical
evidence to support their mask/respirator intervention
effectiveness parameters. However, there is a growing
body of research in this area. An initial systematic review
on the topic reported pooled efficacy measures from
case control studies for N95 respirators and medical
masks of 91 and 68 % respectively for the prevention of
respiratory viruses [49]. A weakness of this initial review
was that the case control studies included in the meta-
analysis focused exclusively on SARS [50]. As a conse-
quence, it should not be assumed that the conclusions
of this meta-analysis are necessarily true for influenza or
other respiratory infections [51].
The updated edition of this review concluded that
there was no evidence of a significant difference in ef-
fectiveness between N95 respirators and medical masks
[50]. However, this conclusion was heavily influenced by
a single cluster randomised trial by Loeb et al. [27] that
compared N95 respirators and medical masks, both used
selectively in high-risk situations. This trial contained
only 446 HCWs and may have been underpowered to
detect a difference between the arms [28]. Two larger
trials not included in this review have been published
[28, 36]. One of these by Macintyre et al. [28], involving
1669 HCWs, found significantly greater protective
efficacy for continuous N95 use when compared to con-
tinuous medical mask use, but no evidence that selective
N95 use was superior to continuous medical mask use
for the prevention of clinical respiratory illness [28].
Limitations
The limitations of the review include the restriction to
English language articles used in the search of the
Scopus database. Further potential limitations are that
the identification and screening process was carried out
predominantly by one of the authors (SM). Finally, the
limited number of studies identified for inclusion made
it difficult to make general conclusions about cost-
effectiveness.
Recommendations
One key recommendation is that future economic ana-
lyses should attempt to apply clinical mask/respirator ef-
ficacy data, preferably from clinical trials, where this
data is deemed applicable to the infectious agent, inter-
vention and setting, rather than using estimations de-
rived from expert opinion or laboratory testing studies
[31]. In some cases this may not be possible, for ex-
ample, it is not appropriate to extrapolate clinical trial
results for respiratory viruses to tuberculosis and for
ethical reasons, randomised trial data cannot be col-
lected on the effectiveness of a respirator intervention in
HCWs for tuberculosis prevention. While the use of
other types of efficacy data applied in the studies identi-
fied by this review have limitations, the results of the
studies may still have validity. However, the underlying
assumptions made in the analyses do need to be care-
fully considered.
Although economic evaluations have been conducted
for the use of mask/respirator strategies in HCWs for
tuberculosis, the way these evaluations should be used
to inform policy needs to be carefully considered. Cost-
effectiveness criteria should only be one part of the deci-
sion making process for any intervention and there may
be specific cases where this factor should be given less
weight. Economic evaluations would be of less relevance
to a decision maker in situations and settings where a res-
pirator would be used regardless of its cost-effectiveness,
but they may be more useful in evaluating situations
where these devices are not currently recommended in a
given setting.
Future evaluations should report their results in such
a way that would allow them to be easily compared to
other non-pharmaceutical or pharmaceutical interven-
tions (e.g. cost per quality-adjusted life year (QALY)
gained). If an evaluation fails to report results in an ap-
propriate format, this limits its use for decision making
as it means that the value of mask/respirator interven-
tions cannot be compared with spending on healthcare
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interventions targeted at other diseases [40]. However, in
some cases the use of intermediate outcomes (e.g. cases
prevented) can still be useful for comparing alternative
ways of reducing specific infection events. This may pro-
vide useful information to decision makers.
Future analysts may also want to consider whether
masks/respirators are cost-effective for use by HCWs in
the seasonal influenza context, or if they are only cost-
effective in extreme pandemic scenarios which may ne-
cessitate a stockpiled supply of masks/respirators.
Conclusions
Although the WHO and the CDC recommend that
HCWs use masks for low-risk influenza exposure and
respirators for high-risk influenza or tuberculosis expos-
ure [1–4], there is currently a lack of economic evidence
to support these recommendations. Further robust eco-
nomic evaluations on mask/respirator interventions are
needed.
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